Company intelligence / Profile preview

BioFactura Australia

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

BioFactura Australia is a subsidiary of the US-based BioFactura, established to leverage Australia's clinical trial infrastructure and R&D tax incentives for the development of its biosimilar pipeline. The company focuses on high-value biologics, utilizing its proprietary Stable Selection Process (SSP) platform to develop high-yielding, stable cell lines for biosimilar production. Its lead program is BFI-751, a biosimilar to Stelara (ustekinumab), which has undergone Phase 1 clinical evaluation in Australia. BioFactura Australia serves as a strategic hub for the parent company's global clinical development and regulatory strategy.

Therapeutic areas: ImmunologyRheumatologyDermatologyGastroenterology
Modalities: Monoclonal antibodyBiologicBiosimilar
Industry: Biotech

Beyond the preview

Go deeper on BioFactura Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioFactura Australia.

Explore the full profile